NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is a proprietary oral fixed-dose combination therapy designed to address multiple disease pathways implicated in ALS, and the company is based in Israel with U.S. capital market access.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenuePrimeC and related clinical-stage drug development for ALS and other neurodegenerative diseases.
Discovery and biomarker-based pipeline work supporting future indications and assets.
Customers
NeuroSense does not sell to a broad commercial customer base; its key stakeholders are patients, physicians, regulators, and clinical trial participants involved in the development and eventual use of its therapies. In practice, demand is driven by unmet medical need in ALS and related neurodegenerative diseases, while value creation depends on clinical data, regulatory milestones, and future commercialization partners or healthcare systems.
Patients with ALS are the core end beneficiaries of PrimeC and the main disease population the company is trying to address.
Neurologists and ALS clinics evaluate the clinical data and may prescribe the therapy if approved.
Health Canada, the FDA, and other agencies review the evidence package for safety, efficacy, and manufacturing.
Patients enrolled in studies generate the efficacy, biomarker, and safety data needed for development.
Pharma or biotech partners may support development, commercialization, or geographic expansion.
Strategy
The company’s strategy is to advance PrimeC through late-stage development and regulatory review as a potential treatment for ALS, while using biomarker and multi-pathway science to differentiate its approach. It is also expanding the development narrative beyond a single mechanism by positioning the program around multiple neurodegenerative pathways and by progressing regulatory engagement in Canada.
Regulatory filing is the key gateway from clinical development to potential commercialization.
Late-stage biotech value depends on reproducible efficacy, safety, and biomarker results.
Development-stage biotechs require ongoing capital to fund trials, regulatory work, and operations.
Geography
NeuroSense is headquartered in Israel, with principal executive offices in Herzliya, and it accesses U.S. capital markets through Nasdaq. Its development work is international in nature because clinical trials, regulatory submissions, and future commercialization for a specialty therapy can span multiple markets, including North America and other regulated geographies.
Risks
NeuroSense faces the typical risks of a clinical-stage biotech, where value depends on trial outcomes, regulatory approvals, and access to financing before any product revenue exists. The company’s very small cash balance, dependence on a single lead asset, and exposure to complex neurodegenerative disease biology make execution and funding risk especially important.
- Clinical development riskImpact: CriticalLikelihood: High
PrimeC must demonstrate safety and efficacy in a very difficult disease area before it can become a commercial product.
Exposure: Lead ALS program
- Financing and liquidity riskImpact: CriticalLikelihood: High
Clinical-stage operations require external capital and the company reported very limited cash at year-end.
Exposure: Operating runway
- Single-product concentrationImpact: HighLikelihood: High
The business currently relies heavily on one lead program, so setbacks would have outsized impact.
Exposure: PrimeC
- Regulatory approval riskImpact: HighLikelihood: Medium
The company depends on health authority review and acceptance of its submission package and clinical data.
Exposure: Health Canada and other regulators
Accounting
Judgemental itemsClinical trial and development spending is a major driver of period results and is generally expensed as incurred.
Impact: Affects operating loss and comparability across quarters
The company reports right-of-use assets and lease liabilities, which affect leverage and future cash commitments.
Impact: Affects balance sheet and operating expense presentation
Unpaid clinical, professional, and operating costs can build up when cash is constrained.
Impact: Affects working capital and liquidity analysis
PIPE and other issuances can materially change share count and financing line items.
Impact: Affects dilution and capital structure
Similar listed companies
Publicly listed companies with a comparable business focus.
ProMIS Neurosciences Inc.
PMN · Pharmaceutical Preparations
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Cognition Therapeutics, Inc
CGTX · Biological Products, (No Diagnostic Substances)
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on small-molecule therapies for age-related degenerative diseases of the central nervous system and retina.
Voyager Therapeutics, Inc.
VYGR · Biological Products, (No Diagnostic Substances)
Alpha Cognition Inc.
ACOG · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026